melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 

 

theraTRACE

 

theraTRACE

Melior Pharmaceuticals

              

 

             

 

                 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery gastrointestinal

DSS Model of Colitis
Inflammatory bowel disorders (IBD), including colitis, are destructive diseases.  In this model, IBD is induced through administration of dextran sodium sulfate (DSS) in the drinking water of mice.  This results in epithelial damage and a robust inflammatory response in the colon lasting several days.  Rodents that are treated with DSS develop inflammation of the colon, exhibit diarrhea, rectal bleeding and weight loss.  At Melior, we have established an acute and chronic model of DSS-induced colitis. 

Figure 1:    

                                       DSS Model of colitis IBD

Body Weight and Percent Change in Body Weight.  Mice were dosed with vehicle or Cyclosporin A daily for 11 days.  For five days, animals were administered DSS via drinking water.  The remaining days animals were provided regular drinking water.  Body weights were measured daily.  The Cyclosporin A mice did not display the weight loss observed in vehicle treated mice (Figure A and B).  Data are mean ± SEM and were analyzed using a two-way ANOVA; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared to vehicle-treated mice. 

Figure 2:

DSS Model of Colitis Colon

 

Colon Length and Weight.  Animals were dosed with vehicle or Cyclosporin A for 11 days.  For five days, animals were administered DSS via drinking water.  The remaining days, animals were provided regular drinking wter.  Colons were removed on day 11 of the study and the length and weights were recorded.  There was no significant difference in colon lengths between the groups (C).  The cyclosprin A  group presented with significantly heavier colons compared to the vehicle group (D).  Data are mean ± SEM and were analyzed using One-Way ANOVA; *p<0.05 compared to vehicle.

 

If you are interested in learning more about the DSS - Model of Colitis, please contact models@meliordiscovery.com to start the conversation.